Marketing authorisation holders are to establish quality systems for the performance of pharmacovigilance activities pursuant to Article 8(1) of Implementing Regulation (EU) No 520/2012. In accordance with Article 13 of that Regulation, those quality systems are to be audited. In order to ensure better efficiency of audits, the content of those audits should be further defined in this Regulation. The third party subcontracted to carry out pharmacovigilance tasks in whole or in part on behalf of or in conjunction with marketing authorisation holders should be audited by or on behalf of the marketing authorisation holder and may be inspected by the competent authorities, irrespective of whether or not this obligation is mentioned in the subcontract. It is important that subcontractors have clarity about their obligations, which should be set out in the subcontract, but a subcontract’s shortcomings should not affect the performance of audits and inspections.
Recital 4, Regulation (EU) 2025/1466
In forcesince 22 Jul 2025